Tianeptine

Tianeptine spent three decades mislabeled as a "serotonin reuptake enhancer" before the actual pharmacology caught up with the clinical reputation. The modern picture is much simpler and much more useful for dosing it intelligently: it is a full μ-opioid receptor agonist with a short half-life, whose antidepressant and anxiolytic effects run through a specific hippocampal GABAergic circuit, with downstream glutamatergic remodeling that explains the chronic mood and stress-resilience benefits. Every rule in the protocol — intermittent dosing, hard weekly caps, no stacking with other CNS depressants — falls directly out of this mechanism.

Full μ-Opioid Agonism (The Real Primary Mechanism)#

Tianeptine is not "opioid-like." It is an opioid. Sames' group at Columbia pinned this down definitively in 2014 using G-protein activation and cAMP assays on human receptors, showing full agonism at MOR, low-potency full agonism at DOR, and nothing at KOR.

"We demonstrate that tianeptine is a full agonist at the human μ-opioid receptor (MOR), with an EC50 of 194 nM and no activity at the κ-opioid receptor." — Gassaway MM et al., Translational Psychiatry (2014)

Naltrexone fully reverses the signaling, which rules out any meaningful non-opioid contribution to the acute effect. Practically, this is what produces the warm, anxiolytic, mildly euphoric, pro-social baseline users describe 45–60 minutes after a dose — and it is also why tolerance, dependence, and a textbook opioid withdrawal syndrome develop when dosed daily. The MOR potency is modest compared to classical opioids (EC50 ~194 nM vs. low-nM for morphine), which is why clinical 12.5 mg dosing is therapeutic rather than narcotic. Push the dose into the hundreds of milligrams and that margin disappears.

Hippocampal GABAergic Circuit (Why the Antidepressant Effect Is Real)#

The interesting part is that the chronic antidepressant effect isn't just "opioid euphoria on repeat." It runs through a specific cell population. Conditional knockout work localized the mechanism to MOR expressed on somatostatin-positive GABAergic interneurons in the ventral hippocampus — knock MOR out of those cells and the antidepressant phenotype disappears, even though the animal still has MOR everywhere else.

"Our work indicates that MOR expression on hippocampal GABAergic interneurons is required for both acute and chronic antidepressant-like behavioral effects of tianeptine." — Zhang B et al., Neuropsychopharmacology (2022)

This matters for the user for two reasons. First, it explains why tianeptine has a genuine antidepressant signal distinct from "just feeling high" — the circuit is the same one implicated in stress resilience and anhedonia. Second, it explains why sub-euphoric 12.5 mg clinical dosing still works: you don't need to saturate MOR to hit the interneuron population that matters.

Glutamatergic Remodeling and Stress-Induced Plasticity#

Before the MOR story was confirmed, the tianeptine literature was dominated by work showing that chronic dosing reverses stress-induced dendritic atrophy in the CA3 hippocampus and basolateral amygdala, normalizes glutamate release under stress, and modulates AMPA/NMDA receptor phosphorylation. That work is still valid — it's now understood as downstream of MOR activation rather than a parallel mechanism. The net effect is a compound that blunts the neurostructural damage of chronic cortisol exposure, which is part of why users on long harsh cuts (another chronic-cortisol state) report a disproportionate mood lift from a single 12.5 mg dose on a rest day.

Pharmacokinetics as Mechanism (The Half-Life Is the Trap)#

Tianeptine sodium has a plasma half-life of roughly 2.5 hours, with active metabolite MC5 extending the tail modestly:

"After oral administration, tianeptine was rapidly absorbed (tmax: 0.94 h), with an elimination half-life of 2.5 ± 1.1 h for the parent drug and 7.2 ± 2.1 h for its main metabolite MC5." — Royer RJ et al., European Journal of Clinical Pharmacology (1990)

Bioavailability is ~99%, onset is ~45–60 minutes, and the subjective effect lasts 3–4 hours before fading. This is the single most important PK fact for harm reduction: the compound is an opioid agonist that visibly wears off within an afternoon. Every case of tianeptine use disorder in the literature follows the same mechanical pattern — user feels the effect fading, redoses to maintain it, trains the MOR system on a high-frequency intermittent reinforcement schedule, and develops tolerance and physical dependence within weeks. Published abuse cases cluster around mean daily doses near 1,469 mg/day (Springer & Cubała 2018) — two orders of magnitude above clinical dosing — reached by chasing the short half-life.

The protocol-level takeaway: you use tianeptine because it's short-acting and you feel it leave. You never redose to maintain a level. The sulfate XR salt is not "safer" — it extends exposure, blunts the off-signal, and is exactly the formulation driving the US OTC "gas station heroin" epidemic.

Non-CYP Metabolism (The One Clean Thing About It)#

Tianeptine is metabolized by β-oxidation of its C5 heptanoic side chain rather than through CYP450, producing MC5 and MC3 metabolites cleared renally. This means minimal interaction potential with oral AAS, SERMs, AIs, finasteride, or SSRIs at the hepatic level — a real advantage for physique-focused users already running a polypharmacy stack. The pharmacodynamic interactions (MAOIs, other opioids including kratom, benzos, alcohol, gabapentinoids) are the dangerous ones and are non-negotiable contraindications. The liver leaves it alone; the receptor pharmacology does not.

Common (most users)#

At clinical doses (≤37.5 mg/day) and intermittent nootropic doses, tianeptine is well tolerated — better than SSRIs on most axes. What you're likely to notice:

• Mild nausea in the first 30–60 minutes — take with a small amount of food (not a fatty meal, which blunts Cmax). Resolves with tolerance within the first few doses.
• Dry mouth — hydrate; no further action needed.
• Mild constipation — the μ-opioid signature. Fiber and fluids handle it at clinical doses; if you need a stool softener, you're dosing too often.
• Transient dizziness or mild orthostatic drops — stand up slowly for the first hour post-dose. More noticeable on an empty stomach.
• First-week headache — typically self-limiting within 5–7 days.
• Mild sedation or "warm" anxiolysis for 2–4 hours post-dose — this is the intended effect; time the dose away from heavy lifts or driving until you know your response.
• Minimal sexual side effects — unlike SSRIs, libido and orgasm are generally preserved or enhanced. This is one of the main reasons physique-focused users reach for it over sertraline/escitalopram.

Uncommon (dose-dependent or individual)#

These show up when users drift past 37.5 mg/day, start dosing daily, or redose to chase the short half-life:

• Tolerance to the mood lift — develops within days to weeks of daily dosing. The correct response is to stop, not to increase. If you're noticing the 12.5 mg dose "isn't hitting," that's the signal.
• Mild prolactin elevation — opioid-mediated. Rarely clinically relevant at sane doses, but worth keeping in mind if you're already managing prolactin on a 19-nor cycle. Check prolactin if you notice nipple tenderness or libido drop.
• Compulsive redosing / clock-watching — this is not a physical side effect, it's the behavioral early warning of dependence. If you find yourself planning the next dose, you're already in the early phase. Stop here, not later.
• Mild LFT bumps — uncommon at label dosing given non-CYP metabolism, but check ALT/AST quarterly if you're running tianeptine alongside oral AAS.
• Insomnia from late-in-the-day dosing — keep doses before 4 PM.
• Appetite suppression or mild GI slowing at 25–37.5 mg — manage with timing around meals.

Rare but serious#

Low incidence but high severity. These are the reasons tianeptine has the reputation it does:

• Physical dependence with opioid-pattern withdrawal — myalgia, GI distress, rhinorrhea, piloerection, cravings, insomnia, dysphoria, anxiety. Indistinguishable from short-acting opioid withdrawal. Case series document users escalating to ~1,469 mg/day on average before crashing.

  "The mean tianeptine daily dose in reviewed abuse cases was 1,469 mg, with reports of users experiencing physical dependence and withdrawal symptoms resembling those seen with classical opioids." — Springer & Cubała 2018

• Missed diagnosis in the ER — tianeptine does not appear on standard urine opioid panels, so treating physicians will not recognize the withdrawal syndrome unless you disclose it. Tell them.

  "Withdrawal symptoms were indistinguishable from those of opioid withdrawal and tianeptine is not detected on routine urine drug screens." — Lauhan 2018

• Respiratory depression and death in overdose — particularly when combined with alcohol, benzodiazepines, gabapentinoids, or other opioids. This is a full μ-opioid agonist; overdose physiology is opioid physiology.

• Tianeptine-induced psychosis at supra-clinical doses — documented but uncommon.

• Seizures — reported in high-dose abuse and abrupt withdrawal contexts.

• Adulterant poisoning from US OTC products — ZaZa, Tianaa, Neptune's Fix, Pegasus, and similar "supplement" bottles have tested positive for undisclosed synthetic cannabinoids and massively supra-clinical tianeptine doses. Do not buy these. Ever.

Warning signs — stop immediately:

• You're dosing more than 3 days per week
• You're redosing within the same day to extend effects
• You're hiding use from partners or friends
• Withdrawal-like symptoms (GI distress, restlessness, cravings) appear when you skip a day
• Buprenorphine-naloxone has been used successfully to manage tianeptine use disorder if it's already gotten away from you — seek it rather than white-knuckling a severe opioid withdrawal.

Hard contraindications#

These lines do not get crossed:

• MAO inhibitors — classic tricyclic-class contraindication; risk of hypertensive and serotonergic crisis.
• Active opioid use, opioid use disorder history, or kratom use — cross-tolerance and compounded μ-opioid dependence. Prior SUD is the single strongest predictor of tianeptine abuse in the case-series literature.
• Benzodiazepines, alcohol, gabapentinoids, Z-drugs, or any CNS depressant at the same dosing — additive respiratory depression. This is an opioid; treat the stacking rules as opioid stacking rules.
• OTC "gas station" tianeptine products (ZaZa, Tianaa, Neptune's Fix, Pegasus and similar) — supra-clinical dosing plus undisclosed adulterants. The product category driving the current US poison-control surge.
• Severe renal impairment — dose reduction required; not a casual nootropic candidate in this population.
• Daily dosing above the 37.5 mg/day clinical ceiling — this is where dependence lives. The therapeutic window closes hard.

Gender-specific and PCT considerations#

Tianeptine has no hormonal activity, no HPTA effect, no aromatization, and no androgenic signal. Women can use the same doses as men — no virilization risk, no cycle-timing considerations. It is not a PCT compound and does not interfere with a SERM-based PCT, but the μ-opioid agonism can mildly elevate prolactin, which is worth noting if you're already watching prolactin coming off a 19-nor. No post-cycle tapering of tianeptine itself is needed provided you stayed inside the intermittent protocol. If you dosed daily for more than a couple of weeks, taper over 7–14 days or bridge with buprenorphine under supervision rather than quitting cold — opioid-pattern withdrawal from this compound is not a "tough it out" situation.